Navigation Links
Senior Executive to Share Views On Physician Payment Sunshine Provisions
Date:6/15/2011

ELLICOTT CITY, Md., June 15, 2011 /PRNewswire/ -- Adam Chasse, vice president for business development at RxTrials, Inc., will participate in a presentation on Capitol Hill this Friday, June 17, regarding the Physician Payment Sunshine provisions of the health care reform legislation passed last year. Chasse will join representatives of the Association of Clinical Research Organizations (ACRO) and other industry stakeholders in the briefing for legislative staffers.

The Physician Payment Sunshine provisions were part of the Patient Protection and Affordable Care Act signed into law on March 23, 2010. The provisions require drug and medical device manufacturers to publicly report gifts and payments of more than $10 made to physicians and teaching hospitals. Examples of what must be reported include stock options, consulting fees, travel and lodging for conferences, honoraria, and research funding or grants. Reporting is to begin for payments in the 2012 calendar year. The information is to be fully reported by March 31, 2013, and posted in a searchable database starting September 30, 2013.

It is the opinion of Chasse and other clinical research industry professionals that disclosing payments made to physicians who serve as principal investigators for clinical research adds great cost and complexity to research & development for relatively small benefit.

"Research grants differ from consulting fees in that they are intended to cover the very real costs providers incur when conducting clinical research; average profit margins are minimal, so grants are unlikely to entice physicians to write more prescriptions for the pharma company's drug," Chasse said. "Plus, grants typically flow through one or more intermediaries such as a CRO, research management company, or university, making it very difficult to quantify what the physician actually receives. Our goal on Friday is to explain the challenges these provisions present to our industry."

Chasse/RxTrials

RxTrials, Inc., is a network of premier clinical research sites and parent company of RxTrials Institute, a leading national clinical research consultant and education provider. RxTrials Institute each year presents the Site Solutions Summit, a top networking and business management conference for clinical research sites, sponsors and CROs. The Summit takes place this year October 14 – 16 in Palm Beach Gardens, Florida (sitesolutionssummit.com).


'/>"/>
SOURCE RxTrials, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. More Than 1.5 Million Americans Sickened, Injured or Killed by Medication Errors Each Year; Seniors Most at Risk
2. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
3. Seniors Can Be Heartened by New Study on Statins
4. VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development
5. Curemark Announces Senior Executive Promotions
6. HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC
7. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
8. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
9. National Long Term Care Leaders Praise Senator Snowes Recognition of Nursing Homes Unique Funding Challenges in Caring for Nations Seniors
10. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
11. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Yissum Research Development ... today that it had signed an exclusive world-wide licensing ... of novel protein degradation and immunomodulatory drugs for cancer ... drug candidates representing first-in-class therapy for hematologic and solid ... The novel technology was developed by ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... A local ... that more than 40 percent of participating fifth-grade students already have or are ... and Asthma Clinical Research in the Division of Pulmonary, Allergy and Critical Care ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Dr. Benjamin ... in non-surgical hair loss treatment. Dr. Stong is double board certified and the ... for the treatment of hair loss. Non-surgical therapies such as stem cells can ...
(Date:5/5/2016)... , ... May 05, 2016 , ... The 2016 Nike ... Derek Pittman, along with his university coaching staff. Together they bring their winning Vandals ... sessions run for youth players ages 5-13, and high school players. Session dates are ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy ... alleviate the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies ... with arthritis. , “Physical therapy exercises are commonly prescribed to individuals with ...
(Date:5/5/2016)... ... May 05, 2016 , ... The Lung Institute will celebrate its three-year ... seminar at most clinic locations throughout the month of May. To date, the Lung Institute ... rapid growth that we’ve seen is a testament to the success of this treatment and ...
Breaking Medicine News(10 mins):